

DR JULIE JACOBSON, MD, DTM&H, FASTMH

Vashon WA 98070 · 206.979.9434 Email jjacobson@bridgestodevelopment.org
LinkedIn: @JulieJacobson Twitter: @DrJulieJ

Global Health Leader: Innovation | Creative Problem Solving | Tropical Diseases | Vaccines | Collaborative Partnerships | Community Outreach

Julie Jacobson is a family practice physician with training in clinical tropical medicine and applied epidemiology. She has dedicated her career to increasing equity in access to health care and preventative services through scale up of innovation, targeted research, and partnership. She is currently co-Founder and Managing Partner of Bridges to Development. Through this new organization founded in 2018, Bridges has led new innovations in immunization, and NTDs including work in female genital schistosomiasis and supporting global disease elimination and eradication efforts. Prior, she worked with the Bill & Melinda Gates Foundation Neglected Tropical Diseases (NTD) team focused on advancing solutions for populations with the least access to care. She was the Initiative Lead for the Guinea worm eradication and diseases approached through Preventative Chemotherapy (PC). She helped to establish and build the foundation's approach to NTDs. She pursued innovative and creative solutions to problems overcoming barriers to access and policy like the invention of the LoaScope, a cellphone based quantifiable diagnostic for Loa loa, and the triple drug therapy for LF which will accelerate global elimination with free drugs.

Through the London Declaration on NTDs in 2012 she founded Uniting to Combat NTDs which built a new innovative partnership to support achieving the WHO 2020 targets for ten neglected diseases and brought together a diverse set of partners for collective problem solving and accountability across implementation partners, researchers, pharmaceutical companies, WHO and endemic countries. She served as founding and first Chair of their governing body, the Stakeholders Working Group.

At PATH she was the Scientific Director of Immunization Solutions and Director of PATH's Japanese encephalitis (JE) project. During this time, she helped accelerate the control of JE in endemic countries by improving data on the distribution of JE, supporting vaccination policy for disease control, the development of an improved vaccine and diagnostic tests for JE and facilitated countries' integration of the JE vaccine into immunization programs. This program supported the first Chinese vaccine ever to be pre-qualified by the World Health Organization and procured by GAVI. Along with PATH's Children's Vaccine Program she supported the start of GAVI and the Vaccine Fund as part of a small team dedicated to ensuring access to vaccines in the developing world and a policy framework for the introduction of new vaccines. Beyond routine immunization she was responsible for prioritizing and designing field activities to support introduction for new vaccines including HPV, yellow fever, and rotavirus.

Before PATH, Dr. Jacobson worked at the U.S. Centers for Disease Control and Prevention as an Epidemic Intelligence Officer working in Disaster Epidemiology responding to natural disasters where she helped inform and design relief responses including health, sanitation, and food security while ensuring that interventions ultimately lead to community development.

Professional Experience & Selected Achievements

Bridges to Development, Geneva, Vashon WA

(2018 – present)

Co-Founder and Managing Partner

Co-Founder and Managing Partner of Bridges to Development (US), a non-profit, founded in 2018 and based in Europe and the US. Bridges works in health and education to build a stronger and more resilient future. Bridges guides and facilitates projects and investments that bridge the gap in access and opportunity, cultivating innovative partnerships and embracing new technologies engaging the communities and invested stakeholders in being part of identifying and refining solutions and approaches that are both creative and effective. Applying knowledge of the three partners from over 25 years of experience with the Bill & Melinda Gates Foundation, Gavi, and the Global Fund the team supports new innovations into policy and scale up. Currently she is focusing on NTDs, with particular emphasis on FGS and broadly on NTD disease elimination/eradication efforts.

Bill & Melinda Gates Foundation, Seattle, WA

(2007 - 2018)

Initiative Lead Oncho, LF, GW, and London Declaration, Neglected Tropical Disease Team (2016-2018)

Refined and focused the strategy on the 10 diseases included in the London Declaration on NTDs with attention on 7 diseases (LF, oncho, STH, schisto, VL, HAT, and Guinea worm). Helped establish NTDs as a foundation priority for 2017 in celebration of the 5th anniversary of the London Declaration and the Uniting to Combat NTD partnership. This allowed the team to leverage the full foundation voice in support of the NTD agenda. Led the triple therapy for LF, which was designated as the top priority for the Global Health division. Partnered to establish NTD programs now reaching over 1 billion people annually as a stepping stone to primary health care access (PHC) and universal health care (UHC).

- Led a strategy for the Triple Therapy for LF that resulted, in record time, in a WHO recommendation for use, an expanded donation for drugs for use in the treatment, country commitments to introduce in India, Papua New Guinea, and Kenya, as well as donor support for introduction (JICA, USAID, BMGF and END Fund).
- Pioneered the development of a solution to overcoming critical barriers to impact, like Loa loa. This included novel strategy development and development of an inventive new diagnostic (LoaScope) using cell phone detection of worm movement in blood.
- As the Chair of the Uniting Stakeholders Working Group for Uniting to Combat NTDs, coordinated the 5th anniversary celebrations with the Uniting Support Center, report launch at the UHC Forum in Japan, and the NTD Summit in Geneva. At the Summit 812 M USD was leveraged for NTD programs.
- Helped to create the new Oncho and LF Elimination Partnership with the Crown Prince Court in Saudi Arabia with a new fund announced in Dec 2017 with a target of 100M USD.
- Held the first forum with BMGF, DFID, Uniting, and WHO on NTDs and women and girls which established the
 collective action to show gender equity in NTD programs. Established a Gender Equity Working Group within
 Uniting to continue this work moving forward and expanding to a broader equity perspective.

Initiative Lead PC NTDs, GW and London Declaration, Neglected Infectious Diseases Team (2012 – 2016)

Took responsibility for all activities following the London Declaration and ensuring that we met our commitment and supported the development of the new partnership across the diverse set of partners. Also worked to create a supportive and collaborative approach to operational research and modeling focused on the PC diseases (LF, oncho, schisto, STH, and trachoma).

- Established the Uniting to Combat NTDs global partnership including civil society, pharma, donors, and researchers in support of endemic countries and WHO. Developing the organization's structure, governance, and the scorecard to follow progress across all 10 diseases in line with the WHO NTD roadmap.
- Created the Coalition for Operational Research on NTDs (COR-NTD) which worked to be a more flexible model for investing in research to address key operational and program barriers to achieving the 2020 goals. This mechanism has been so successful that USAID and DFID provided support through this same mechanism.
- Supported our first investment to WHO AFRO to improve data quality and complete the NTD PC mapping with the creation of an NTD online portal, now the ESPEN NTD Portal.
- Created the NTD Modeling consortium to help define evidence-based targets and define testable hypotheses for accelerating progress towards the 2020 goals.
- Created the first STH strategy for BMGF which added an additional 50M USD internally which she leveraged for matching with 100M from external funders to push forward the STH agenda.
- After an extensive review and program analysis got continued commitment to GWEP to fund 50% of program through eradication.

Senior Program Officer, Neglected and Other Infectious Diseases (2009 – Jan 2012)

A founding member of this new team defining our strategy and approach to a diverse set of pathogens and approaches including NTDs, dengue, HPV, and maternal immunization.

- Coordinated the first strategy for NTDs and "other" infectious diseases for the foundation.
- Wrote the London Declaration on NTDs leveraging financial and drug donations via the Gates CEO Roundtable, focused on supporting countries to achieve the WHO NTD roadmap goals for 10 NTDs leveraging commitments from 9 pharma companies, and 845M USD in funding.
- Wrote and initiated the grant making for the dengue strategy expanding the approach from a vaccine development focus to a broader set of wholistic investments including vector control, surveillance, and partnership building.
- Drove the BMGF strategic response for maternal immunization after an unexpected finding of significant

- benefit to neonates from maternal immunization with flu vaccine.
- Helped develop the foundation's first Delivery strategy defining the foundation's potential unique role in delivery moving past a product development focused agenda to getting to impact.

Senior Technical Officer for Epidemiology and Surveillance, Infectious Diseases (2007-2009)

Joined the foundation to help define the strategy at a time of new growth with the new investment from Warren Buffet. I worked across the Infectious Diseases team and took responsibility for our work in the neglected diseases and for cross foundation initiatives from the ID team like the newly forming Delivery team representing our efforts in malaria, enteric diseases, pneumonia, and "other" infectious diseases.

- Set the ground work for defining a work stream and strategy for neglected diseases.
- Successfully got 40 M USD funding for the GWEP with special initiative funding.
- Helped to establish and expand the mandate for the Global Network for NTDs which supported NTD advocacy
 to get new bilateral and private funding for NTD programs focused on the preventive chemotherapy diseases.

Program for Appropriate Technology in Health (PATH), Seattle

(2000 - 2007)

Scientific Director, Immunization Solutions (IMM) (2006 – 2007)

Provided scientific oversight to the portfolio of projects within IMM and has overall responsibility for the scientific and technical rigor in the design and implementation of IMM proposals and projects. Participated in the design, monitoring and evaluation of clinical research and clinical trials, developed IMM staff capacity in applying scientific and public health principles, and represented IMM to donors, representatives of government agencies, and others on scientific and technical matters and was the designated manager of high profile or especially complex IMM projects.

• Projects in IMM's portfolio include; Hib, including an impact study in Senegal; Rotavirus including vaccine introduction, clinical trials, and surveillance work; HPV including demonstration projects and evaluating barriers to adolescent immunization; and JE (as below).

Director, Japanese encephalitis (JE) Project (2003 – 2007)

Directed a multinational team responsible for control of clinical JE through vaccination. Managed day-to-day JE projects and development of overall program strategy and design, which included: hiring of staff; negotiations with industry and public-sector partners; design of field activities, such as model programs, vaccine trials, disease-burden studies, field-program monitoring and evaluation; design of field-trial protocols and analysis of epidemiological studies; and management of JE field activities. Represented the project and coordinated activities between partners, ministries of health, nongovernmental organizations, and universities.

• Primary author of the awarded grant.

Interim Director, Rotavirus Vaccine Project (2003)

Supported scale-up of Gavi and PATH, managing and supporting programs in SE Asia (e.g. Cambodia, India, Indonesia) and Africa on health system and immunization strengthening, adoption of new vaccines, and financial sustainability. Contributed to establishment of the International Financing Facility for immunization which has disbursed \$2.5B for immunization and secured donor commitments of \$6.5B. developed distance learning module relating to new vaccine decision-making, financing and economics, and supply and procurement. Analyzed cost- saving group procurement mechanisms for Eastern Europe.

Program Officer (2000 – 2003)

Program Officer in the areas of Japanese encephalitis, human papilloma virus, rotavirus, and yellow fever. Responsible for day-to-day management of specific field projects. Managed selected CVP field activities within the framework of the Global Alliance for Vaccines and Immunization (GAVI) process. Manage and coordinated review and evaluation of CVP-funded activities by collaborating partners. Reviewed annual work plans and progress reports. Conducted site visits. Coordinated activities between partners, ministries of health, nongovernmental organizations, and universities. Provided technical evaluation of proposals and collaboration requests. Prepared reports and articles for publication. Gave presentations at international and regional meetings.

 Co-author of proposals including Hib, common protein vaccine for pneumococcus, HPV vaccine development, and YF control in Africa.

- Assisted in development of overall program strategy and design.
- Prioritized and designed Children's Vaccine Project (CVP) field activities such as model programs, vaccine trials, disease-burden studies, and field-program monitoring and evaluation.
- Designed field-trial protocols and analysis of epidemiological studies.

United States Public Health Service Commissioned Corps

(1998 - 2000)

Epidemic Intelligence Officer, Lieutenant Commander

Provided technical assistance and support in post natural disaster settings evaluating health systems and needs with a cross sector approach including water and sanitation, and food security. The focus was to establish an appropriate emergency response in context of the underlying situation and establish surveillance and evaluation systems that would allow successful transition from emergency response to development aid.

- At request of the Pan-American Health Organization (PAHO), conducted workshops with five South American countries to evaluate health effects from El Niño. Evaluated national surveillance system in Venezuela, Ecuador, and Bolivia and presented results. Evaluated health impact of water, sanitation, and water treatment on health status of displaced persons following an earthquake in Bolivia and presented results of study.
- At request of American Red Cross, conducted household needs assessment in the Dominican Republic following Hurricane Georges, resulting in a one-year grant to provide food to the hurricane-affected population.
- Conducted the largest scale post-disaster needs assessment across Honduras, El Salvador, Guatemala, Belize, and Nicaragua following Hurricane Mitch—to direct relief programming and used for sustainable community development to improve community resilience including water and sanitation.
- At request of Washington State, supported assessment of extent of human exposure to nitrate-containing well water in high-risk counties.

Tallahassee Memorial Regional Medical Center, Tallahassee, Florida

(1995 - 1998)

Family Practice Resident

Performed patient care in obstetrics, gynecology, medicine, pediatrics, community medicine, radiology, ophthalmology, surgery, orthopedics, and intensive care unit patient management.

• Helped establish an international health track at the residency with primary care field experience in El Salvador, Dominican Republic, and Peru.

Dyanyogi Center, Bihar, India

(1994)

Physician

Performed patient care of 57 travelers through India including managing a typhoid outbreak including 5 of our travelers. Aided in the management and re-establishment of a free hospital in Bihar State.

International Rescue Committee, Kibumba Camp Goma, Zaire

(1994)

Medical Director

Provided emergency care leading outreach for the first response within the Kibumba Camp to the humanitarian crisis following the mass exodus of Rwandans following the genocide. Provided care daily to more than 100 patients a day during a Cholera and Shigella outbreak to camp of more than 200,000 refugees. Assessed daily the needs of the camp and developed ways to meet those needs. Collected data for United Nations High Committee on Refugees and CDC to help direct the response.

Created an infant feeding station for feeding infants prior to establishment of a facility.

Karawa Hospital, Karawa, Democratic Republic of Congo

(1994)

Physician

Provided patient care in pediatrics, medicine, surgery, nutrition, tropical medicine, obstetrics, and community medicine.

• Evaluated adequacy of nutritional enhancement program and established augmentation with goat's milk—a local resource.

University of Southern Florida College of Medicine, Tampa, Florida

(1991 - 1994)

Medical Student Volunteer

Performed patient care in under-served populations in The Judeo-Christian Clinic, Ruskin Health Care Clinic, and Dover Health Care Clinic.

Project World Health, Tampa, Florida

(1990 - 1994)

Co-founder / President

Gave numerous speeches around the United States.

- Initiated a medical exchange program in Colombia.
- Initiated a medical supply program assisting Colombia, Belize, Guatemala, Sudan, and The Medical Benevolence Foundation.
- Launched a buddy program at Emory University.
- Initiated and participated in numerous international primary health programs and evaluations in Jamaica, the Czech Republic, and Trinidad.

The Gesundheit Institute, Hillsboro, West Virginia

(1991)

Volunteer

Organized and participated in a group to help build a free hospital in West Virginia, supervised by Patch Adams, M.D.

University of South Florida College of Medicine, Tampa, Florida

(1987 - 1990)

Research Assistant

Measured various-hypertrophic heart cell volume to understand cardiac damage and response. Enumerated regeneration of dorsal horn nerve cell regeneration after neonatal capsacin treatment. Histological identification of early in vitro spermatogenesis. Supported the early work in magnetic resonance imaging (MRI) pattern development.

Bay Pines Veteran's Administration, St. Petersburg, Florida

(1985 - 1986)

Research Assistant

As a high school senior, participated in the executive internship program in the field of biomedical research. Worked on the identification of markers for schizophrenia using snailine as a reagent in immunoelectrophoresis to identify novel human serum proteins. Ran protein immunoelectrophoresis of fish-eye lens as evolutionary markers.

Education, Training & Awards

Education:

D.T.M.& H., Gorgas Memorial Insitute, Cayatano Heredia, Lima, Peru, 1996 **M.D.**, University of South Florida, College of Medicine, Tampa, Florida, 1994 **B.A.**, Biology, University of South Florida, Tampa, Florida, 1990

Professional Training:

Applied Epidemiology, Centers for Disease Control and Prevention Epidemic Intelligence Service, Atlanta, Georgia, 1998

International Health Training in Complex Humanitarian Emergencies, Rainbow Babies and Children's Hospital, Cleveland, Ohio, 1996

International Health Training in the Developing World, University of Arizona, Tucson, Arizona, 1990

Medical Certifications:

National Board of Medical Examiners American Academy of Family Practice

Awards:

- Guinness Book of World Records, Uniting to Combat NTDs for the largest pharmaceutical donation in the world in a 24-hour period, January 30th, 2017
- Dominique Kyeleme Prize for dedication and service to the treatment and prevention of NTDs, April 2015
- Distinguished Physician Alumnus Award, Morsani College of Medicine, University of South Florida Health 2014

- Bill and Melinda Gates Foundation, President recognition award Champagne Toast for achievements with the London Declaration
- Bill and Melinda Gates Foundation High Impact Award 2008
- Ian Hardy Memorial Award, CDC Outstanding contributions to vaccine preventable diseases, 2005
- National Center for Environmental Health Director's Award, Superior Mission Response, 1999
- Outstanding Community Service Award from Ciba-Geigy, 1994
- Outstanding Community Service Award from the Florida Medical Association, 1993
- Project World Health Award, 1993
- University of South Florida Honors Program
- Executive Internship Seminole High School

Board | Chair | & Advisory Roles

- Chair of the WHO Strategic and Technical Advisory Group's Monitoring, Evaluation and Research Working Group, 2021- present
- Special Presidential Advisor, American Society of Tropical Medicine and Hygiene 2022-present
- President, American Society of Tropical Medicine and Hygiene 2020- 2022
- Member of the Hideyo Noguchi Africa Prize Medical Research Selection Committee 2021 and the Hideyo Noguchi Africa Prize African Service Selection Committee 2020
- International Task Force for Disease Eradication, The Carter Center, Task Force Member, 2015- 2018
- AFRO NTD Regional Program Review Group member 2014- 2019
- Chair of the Uniting to Combat NTDs Stakeholders Working Group 2012-2020
- Chair of the Uniting to Combat NTDs Disease Specific Working Group, 2012-2016
- Chair of the Uniting to Combat NTD Donors Working Group 2012-2017
- END Fund, Technical Advisory Board 2012- 2019
- Bio Ventures for Global Health (BVGH) technical advisor to the Global Health Primer, 2010-2012
- Board Member, American Society of Tropical Medicine and Hygiene November 2016- 2019
- Eradication Investment Cases of Onchocerciasis, Lymphatic Filariasis and Human African Trypanosomiasis, Technical Advisory Group (TAG) 2011 to 2015
- Loa loa Test and Treat technical advisory group 2011 to present
- WHO Neglected Tropical Diseases (NTD) Strategic and Technical Advisory Group (STAG) Working Group on Monitoring of Drug Efficacy, BMGF representative 2010 to 2018
- WHO NTD STAG Working Group on Monitoring and Evaluation, BMGF representative 2010 to 2018
- Mectizan Expert Committee/Albendazole Coordination Committee, BMGF representative 2009 to 2018
- Member Loiasis Scientific Working Group 2009 to present
- Board Member; Schistosomiasis Control Initiative 2008-2009
- African Program for Onchocerciasis Control (APOC) Joint Action Forum (JAF) BMGF representative 2008-2015
- Onchocerciasis Elimination in the Americas (OEPA) Program Coordination Committee (PCC) BMGF representative (special guest) 2007 to 2018
- Representative, The Bill and Melinda Gates Foundation; Partnership for Disease Control Initiatives, 2007-2018
- Member; ACIP JE Working Group 2006
- Chair of the WHO JE Laboratory Working Group 2004-05
- Chair of the India JE Interagency Working Group 2003-07
- Chair of the JE Core Working Group 2001-06
- Residency Curriculum Committee, 1996
- Residency Affairs Committee, 1996
- Delegate, International Federation of Medical Student Associations (IFMSA), 1993-94
- Member of the Standing Committee on Refugees of IFMSA, 1993-94
- Member of the Standing Committee on Public Health of IFMSA, 1993-94
- Clerkship Advisory Board Appointee, 1993-94
- Regional Coordinator of American Medical Student Association (AMSA) Task Force on Humanistic Medicine, 1992-93
- Regional Coordinator of AMSA Task Force on International Health, 1992-93
- Regional Liaison for IFMSA, 1992-93
- Co-founder/President of Project World Health, 1991-94

- Vice President of the University of South Florida College of Medicine chapter of AMSA, 1991-92
- University of South Florida Honors Program Graduate, 1990
- Vice President of University of South Florida College of Medicine, class of 1990, 1988-7

Speaking Engagements

- Expert for The Global Institute for Disease Elimination (GLIDE) series of online videos (webisodes) on disease elimination and eradication 2022
- Institute of Medicine (IOM) Public Workshop on "The Causes and Consequences of Neglected Tropical and Zoonotic Diseases" Technical presenter and BMGF representative, September 2010 Speaker, RTI: The Next Frontier in NTD Control: Implementing the Roadmap from the London Declaration's 2020 Goals, National Press Club, Washington DC, April 2012
- Speaker, Grand Rounds Florida State University (FSU) College of Medicine, April 2012
- Speaker, FIHTM Global Health Symposium Keynote Speaker, Washington University April 2012
- Interviewed President Carter and Bill Gates Sr for Townhall meeting at BMGF Feb 2012
- Participant and Author; Ernst Strüngmann Forum, Disease Eradication in the Context of Global Health in the 21st Century 2010
- Speaker; 2010 Voices from the Vanguard Series, University of Georgia 2010
- Speaker and Member; Vaccine Dinner Club, 2008
- Featured in BBC series Kill or Cure for 2 episodes on JE epidemic and then on JE vaccine introduction 2005 and 2006

Publications

Book Chapters:

- 1. Halstead, Scott B, Jacobson, Julie, Dubischar-Kastner, Katrin. Japanese encephalitis vaccines. In: Plotkin S, Orenstein W, Offit P, *Vaccines*, 6th edition. United Kingdom: Elsevier; 2013: 312-352.
- 2. Jacobson, Julie, Rabinovich, Regina. The Bill and Melinda Gates Foundation Approach and Strategy to the Neglected Tropical Diseases 1998-2010. In: Choffners, Eileen R, Relman, David A, The causes and impacts of neglected tropical and zoonotic diseases. Washington, DC: Institute of Medicine, 2011: 293-309.
- 3. Jacobson, Julie. The role of research. In: Cochi, Stephen L, Dowdle, Walter R, Disease eradication in the 21st century. Cambridge, Massachusetts: The MIT Press, 2011: 63-76
- Stoever, Kari, Maher, Chris, Aylward, Bruce R, Jacobson, Julie, Mohamed, Jaffer Ali, John, T Jacob, Scott, Robert S, Wright, Andy. Group report: elements of good governance in disease eradication initiatives. In: Cochi, Stephen L, Dowdle, Walter R, Disease eradication in the 21st century. Cambridge, Massachusetts: The MIT Press, 2011: 191-199
- 5. Halstead, Scott B, Jacobson, Julie. Japanese encephalitis vaccines. In: Plotkin S, Orenstein W, Offit P, *Vaccines*, 5th edition. United Kingdom: Elsevier; 2008: 311-352.

Journal Articles.

- Aribodor OB, Mogaji HO, Surakat OA, et al. Profiling the knowledge of female medical/para-medical students, and expertise of health care professionals on female genital schistosomiasis in Anambra, South Eastern Nigeria. PLoS Negl Trop Dis. 2023;17(2):e0011132. Published 2023 Feb 16. doi:10.1371/journal.pntd.0011132
- 2. Vlassoff C, Arogundade K, Patel K, Jacobson J, Gyapong M, Krentel A. Improving the Response of Health Systems to Female Genital Schistosomiasis in Endemic Countries through a Gender-Sensitive Human Rights-Based Framework. Diseases. 2022;10(4):125. Published 2022 Dec 14. doi:10.3390/diseases10040125
- 3. Jacobson J. Brave New World[†] [published online ahead of print, 2022 Aug 22]. Am J Trop Med Hyg. 2022;107(4):733-739. doi:10.4269/ajtmh.22-0447
- 4. Jacobson J. Compressing the Timelines for Development and Delivery: Accelerating Access to Triple-Drug Therapy to Eliminate Lymphatic Filariasis. Am J Trop Med Hyg. 2022;106(5_Suppl):4-12. Published 2022 Mar 15. doi:10.4269/ajtmh.21-1174

- 5. King JD, Jacobson J, Krentel A. Accelerating the Uptake of WHO Recommendations for Mass Drug Administration Using Ivermectin, Diethylcarbamazine, and Albendazole. Am J Trop Med Hyg. 2022;106(5 Suppl):26-28. Published 2022 Mar 15. doi:10.4269/ajtmh.21-0972
- Ghosh RS, Haldar P, Jacobson J. Lessons Learned from the Japanese Encephalitis Vaccine Introduction in India That Supported the Introduction of Ivermectin-Diethylcarbamazine-Albendazole for Lymphatic Filariasis Elimination. Am J Trop Med Hyg. 2022;106(5_Suppl):48-55. Published 2022 Mar 15. doi:10.4269/ajtmh.21-1168
- 7. Jacobson J, Brooks A. Reflections on "Orchestrating for Impact": Harmonizing across Stakeholders to Accelerate Global Health Gains. Am J Trop Med Hyg. 2022;106(5_Suppl):67-69. Published 2022 Mar 15. doi:10.4269/ajtmh.21-1101
- 8. Jacobson J, Pantelias A, Williamson M, et al. Addressing a silent and neglected scourge in sexual and reproductive health in Sub-Saharan Africa by development of training competencies to improve prevention, diagnosis, and treatment of female genital schistosomiasis (FGS) for health workers. Reprod Health. 2022;19(1):20. Published 2022 Jan 24. Available at: https://doi.org/10.1186/s12978-021-01252-2
- 9. Jacobson J. Wisdom on the 3 Cs-Compassion, Culture, and Courage-from One of My Heroes, President Jimmy Carter. Am J Trop Med Hyg. 2022;106(1):10-11. Published 2022 Jan 5. Available at: https://doi.org/10.4269/ajtmh.21-1147
- 10. Engelman D, Marks M, Steer AC, Beshah A, Biswas G, Chosidow O, Coffeng LE, Lardizabal Dofitas B, Enbiale W, Fallah M, Gasimov E, Hopkins A, Jacobson J, Kaldor JM, Ly F, Mackenzie CD, McVernon J, Parnaby M, Rainima-Qaniuci M, Sokana O, Sankara D, Yotsu R, Yajima A, Cantey PT. A framework for scabies control. PLoS Negl Trop Dis. 2021 Sep 2;15(9):e0009661. Available at: 10.1371/journal.pntd.0009661
- 11. Harrel E, Berland L, Jacobson J, Addiss DG. Compassionate Leadership: Essential for the Future of Tropical Medicine and Global Health. Am J Trop Med Hyg. 2021;105(6):1450-1452. Published 2021 Oct 11. Available at: doi:10.4269/ajtmh.21-0832
- 12. Bradley M, Taylor R, Jacobson J, et al. Medicine donation programmes supporting the global drive to end the burden of neglected tropical diseases [published correction appears in Trans R Soc Trop Med Hyg. 2021 May 8;115(5):575]. Trans R Soc Trop Med Hyg. 2021;115(2):136-144. Available at: doi:10.1093/trstmh/traa167
- 13. Vannice, K. S., Hills, S. L., Schwartz, L. M., Barrett, A. D., Heffelfinger, J., Hombach, J., Letson, G. W., Solomon, T., Marfin, A. A., & Japanese encephalitis vaccination experts panel (2021). The future of Japanese encephalitis vaccination: expert recommendations for achieving and maintaining optimal JE control. NPJ vaccines, 6(1), 82. https://doi.org/10.1038/s41541-021-00338-z
- 14. Rosenthal PJ, Bausch DG, Goraleski KA, et al. Keep Politics out of Funding Decisions for Medical Research and Public Health. Am J Trop Med Hyg. 2020;103(3):931-932. doi:10.4269/ajtmh.20-0850
- 15. Weil GJ, Jacobson JA, King JD. A triple-drug treatment regimen to accelerate elimination of lymphatic filariasis: From conception to delivery. Int Health. 2020 Dec 22;13(Supplement_1):S60–4.
- 16. Colley DG, Jacobson JA, Binder S. Schistosomiasis Consortium for Operational Research and Evaluation (SCORE): Its Foundations, Development, and Evolution. Am J Trop Med Hyg. 2020 Jul;103(1_Suppl):5–13.
- 17. The Ivermectin Roadmappers, Billingsley P, Binka F, Chaccour C, Foy B, Gold S, et al. A Roadmap for the Development of Ivermectin as a Complementary Malaria Vector Control Tool. Am J Trop Med Hyg. 2020 Feb;102(2s):3–24.
- 18. Epidemic Intelligence Service Officers Past and Present . Open Letter by Epidemic Intelligence Service Officers Past and Present in Support of CDC. Epimonitor. 2020;41(10):12-18.
- 19. Means AR, Krentel A, Theobald S, Dean L, Mbabazi PS, Elphick-Pooley T, et al. Catalyzing NTD gender and equity research: A call for papers. PLoS Negl Trop Dis. 2018 Oct;12(10):e0006681.

- 20. Lenk, E. J., Redekop, W. K., Luyendijk, M., Fitzpatrick, C., Niessen, L., Stolk, W. A., Tediosi, F., Rijnsburger, A. J., Bakker, R., Hontelez, J., Richardus, J. H., Jacobson, J., Le Rutte, E. A., de Vlas, S. J., & Severens, J. L. (2018). Socioeconomic benefit to individuals of achieving 2020 targets for four neglected tropical diseases controlled/eliminated by innovative and intensified disease management: Human African trypanosomiasis, leprosy, visceral leishmaniasis, Chagas disease. PLoS neglected tropical diseases, 12(3), e0006250. https://doi.org/10.1371/journal.pntd.0006250
- 21. Jacobson J, Bush S. Neglected Tropical Diseases, Neglected Communities, and Conflict: How Do We Leave No One Behind? Trends Parasitol. 2017 Nov 20. pii: S1471-4922(17)30269-6. doi: 10.1016/j.pt.2017.10.013. [Epub ahead of print] PubMed PMID: 29162404.
- 22. Theobald S, MacPherson EE, Dean L, Jacobson J, Ducker C, Gyapong M, Hawkins K, Elphick-Pooley T, Mackenzie C, Kelly-Hope LA, Fleming FM, Mbabazi PS. 20 years of gender mainstreaming in health: lessons and reflections for the neglected tropical diseases community. BMJ Glob Health. 2017 Nov 12;2(4):e000512. doi: 10.1136/bmjgh-2017-000512. eCollection 2017. Review. PubMed PMID: 29177100; PubMed Central PMCID: PMC5687534.
- 23. Redekop WK, Lenk EJ, Luyendijk M, Fitzpatrick C, Niessen L, Stolk WA, Tediosi F, Rijnsburger AJ, Bakker R, Hontelez JA, Richardus JH, Jacobson J, de Vlas SJ, Severens JL. The Socioeconomic Benefit to Individuals of Achieving the 2020 Targets for Five Preventive Chemotherapy Neglected Tropical Diseases. PLoS NeglTrop Dis. 2017 Jan 19;11(1):e0005289. doi: 10.1371/journal.pntd.0005289. eCollection 2017 Jan. PubMed PMID: 28103243; PubMed Central PMCID: PMC5313231.
- 24. Fischer PU, King CL, Jacobson JA, Weil GJ. Potential Value of Triple Drug Therapy with Ivermectin, Diethylcarbamazine, and Albendazole (IDA) to Accelerate Elimination of Lymphatic Filariasis and Onchocerciasis in Africa. PLoS Negl Trop Dis. 2017 Jan 5;11(1):e0005163. doi: 10.1371/journal.pntd.0005163. eCollection 2017 Jan. PubMed PMID: 28056015; PubMed Central PMCID: PMC5215784.
- 25. Means AR, Jacobson J, Mosher AW, Walson JL. Integrated Healthcare Delivery: A Qualitative Research Approach to Identifying and Harmonizing Perspectives of Integrated Neglected Tropical Disease Programs. PLoS Negl Trop Dis. 2016 Oct 24;10(10):e0005085. doi: 10.1371/journal.pntd.0005085. eCollection 2016 Oct. PubMed PMID: 27776127; PubMed Central PMCID: PMC5077162.
- 26. Means AR, Ásbjörnsdóttir K, Mwandawiro C, Rollinson D, Jacobson J, Littlewood T, Walson JL. Sustaining Progress towards NTD Elimination: An Opportunity to Leverage Lymphatic Filariasis Elimination Programs to Interrupt Transmission of Soil-Transmitted Helminths. PLoS Negl Trop Dis. 2016 Jul 14;10(7):e0004737. doi: 10.1371/journal.pntd.0004737. eCollection 2016 Jul. PubMed PMID: 27416062; PubMed Central PMCID: PMC4944981.
- 27. Stolk WA, Kulik MC, le Rutte EA, Jacobson J, Richardus JH, de Vlas SJ, Houweling TA. Between-Country Inequalities in the Neglected Tropical Disease Burden in 1990 and 2010, with Projections for 2020. PLoS Negl Trop Dis. 2016 May 12;10(5):e0004560. doi: 10.1371/journal.pntd.0004560. eCollection 2016 May. PubMed PMID: 27171193; PubMed Central PMCID: PMC4865216.
- 28. Toledo CE, Jacobson J, Wainwright EC, Ottesen EA, Lammie PJ. RRR for NNN-a rapid research response for the Neglected Tropical Disease NGDO Network: a novel framework to challenges faced by the global programs targeting neglected tropical diseases. Int Health. 2016 Mar;8 Suppl 1:i12-4. doi: 10.1093/inthealth/ihv072. PubMed PMID: 26940303; PubMed Central PMCID: PMC4777228.
- 29. de Vlas SJ, Stolk WA, le Rutte EA, Hontelez JA, Bakker R, Blok DJ, Cai R, Houweling TA, Kulik MC, Lenk EJ, Luyendijk M, Matthijsse SM, Redekop WK, Wagenaar I, Jacobson J, Nagelkerke NJ, Richardus JH. Concerted Efforts to Control or Eliminate Neglected Tropical Diseases: How Much Health Will Be Gained? PLoS Negl Trop Dis. 2016 Feb 18;10(2):e0004386. doi: 10.1371/journal.pntd.0004386. eCollection 2016 Feb. PubMed PMID: 26890362; PubMed Central PMCID: PMC4758649.
- 30. Matheson AI, Manhart LE, Pavlinac PB, Means AR, Akullian A, Levine GA, Jacobson J, Shutes E, Walson JL. Prioritizing countries for interventions to reduce child mortality: tools for maximizing the impact of mass drug administration of azithromycin. PLoS One. 2014 May 16;9(5):e96658. doi:

- 10.1371/journal.pone.0096658. eCollection 2014. PubMed PMID: 24837459; PubMed Central PMCID: PMC4023929.
- 31. Freeman MC, Ogden S, Jacobson J, Abbott D, Addiss DG, Amnie AG, Beckwith C, Cairncross S, Callejas R, Colford JM Jr, Emerson PM, Fenwick A, Fishman R, Gallo K, Grimes J, Karapetyan G, Keene B, Lammie PJ, Macarthur C, Lochery P, Petach H, Platt J, Prabasi S, Rosenboom JW, Roy S, Saywell D, Schechtman L, Tantri A, Velleman Y, Utzinger J. Integration of water, sanitation, and hygiene for the prevention and control of neglected tropical diseases: a rationale for inter-sectoral collaboration. PLoS Negl Trop Dis. 2013 Sep 26;7(9):e2439. doi: 10.1371/journal.pntd.0002439. eCollection 2013. Review. PubMed PMID: 24086781; PubMed Central PMCID: PMC3784463.
- 32. Krolewiecki AJ, Lammie P, Jacobson J, Gabrielli AF, Levecke B, Socias E, Arias LM, Sosa N, Abraham D, Cimino R, Echazú A, Crudo F, Vercruysse J, Albonico M. A public health response against Strongyloides stercoralis: time to look at soil-transmitted helminthiasis in full. PLoS Negl Trop Did 2013 May; 9: 7(5):e2165.
- 33. Campbell GL, Hills SL, Fischer M, Jacobson JA, Hoke CH, Hombach JM, Marfin AA, Solomon T, Tsai TF, Tsu VD, Ginsburg AS. Estimated global incidence of Japanese encephalitis: a systematic review. Bull World Health Organ. 2011 Oct; 89(10):766-7
- 34. Khalakdina A, Shrestha SK, Malla S, Hills S, Thaisomboonsuk B, Shrestha B, Gibbons RV, Jacobson J. Field evaluation of commercial Immunoglobulin M antibody capture ELISA diagnostic tests for the detection of Japanese encephalitis virus infection among encephalitis patients in Nepal. Int J Infect Dis 2010 Sept; 14(3):e79-84.
- 35. Hills, S. L., Van Cuong, N., Touch, S., Mai, H. H., Soeung, S. C., Lien, T. T., Samnang, C., Sovann, L., Van Diu, P., Lac, L. D., Heng, S., Huong, V. M., Grundy, J. J., Huch, C., Lewthwaite, P., Solomon, T., & Jacobson, J. A. (2011). Disability from Japanese encephalitis in Cambodia and Viet Nam. *Journal of tropical pediatrics*, *57*(4), 241–244. https://doi.org/10.1093/tropej/fmp133
- 36. Hills S, Dabbagh A, Jacobson J, Marfin A, Featherstone D, Hombach J, Namgyal P, Rani M, Solomon T; Japanese Encephalitis Core Working Group. Evidence and rationale for the World Health Organization recommended standards for Japanese encephalitis surveillance. BMC Infect Dis 2009 Dec; 9(1):214.
- 37. Maha MS, Moniaga VA, Hills SL, Widjaya A, Sasmito A, Hariati R, Kupertino Y, Artastra IK, Arifin MZ, Supraptono B, Syarif I, Jacobson JA, Sedyaningsih R. Outcome and extent of disability following Japanese encephalitis in Indonesian children. Int J Infect Dis 2009 Nov; 13(6):e389-93.
- 38. Singhasivanon P, Jacobson J. Dengue is a major global health problem. Foreword. J Clin Virol 2009 Oct; 46 Suppl 2:S1-2.
- 39. Touch S, Grundy J, Hills S, Rani M, Samnang C, Khalakdina A, Jacobson J. <u>The rationale for integrated childhood meningoencephalitis surveillance: a case study from Cambodia.</u> Bull World Health Organ 2009 Apr; 87(4):320-4.
- 40. Hotez PJ, Brindley PJ, Bethony JM, King CH, Pearce EJ, Jacobson J. Helminth infections: the great neglected tropical diseases. J Clin Invest 2008 Apr; 118(4):1311-21.
- 41. Ompusunggu S, Hills SL, Maha MS, Moniaga VA, Susilarini NK, Widjaya A, Sasmito A, Suwandono A, Sedyaningsih ER, Jacobson JA. Confirmation of Japanese encephalitis as an endemic human disease through sentinel surveillance in Indonesia. Am J Trop Med Hyg 2008 Dec; 79(6):963-70.
- 42. Gatchalian S, Yao Y, Zhou B, Zhang L, Yoksan S, Kelly K, Neuzil KM, Yaïch M, Jacobson J. Comparison of the immunogenicity and safety of measles vaccine administered alone or with live, attenuated Japanese encephalitis SA 14-14-2 vaccine in Philippine infants. Vaccine. 2008 Apr 24; 26 (18):2234-41.
- 43. Jacobson J, Hills SL, Winkler JL, Mammen M, Thaisomboonsuk B, Marfin AA, Gibbons RV. Evaluation of three immunoglobulin M anitobody capture enzyme-linked immunosorbent assays for diagnosis of Japanese Encelphalitis. Am. J Trop Med Hyg 2007; 77(1):164-168.

- 44. Suraratdecha C, Jacobson J, Sivalenka S, Narahari D. A cost-effectiveness analysis of strategies for controlling Japanese Encephalitis in Andhra Pradesh, India. Journal of Pharmaceutical Finance Economics & Policy 2006; 15(1):21-40.
- 45. Hombach J, Solomon T, Kurane I, Jacobson J, Wood D. Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2-3 September, 2004. Vaccine. 2005 Nov 1; 23(45):5205-11.
- 46. Jacobson J. Working toward more patient-centered integrative care. MedGenMed 2004 Mar 6(1):40.
- 47. Jacobson J, Sivalenka S. Japanese encephalitis globally and in India. Indian J Public Health 2004 Apr-Jun; 48(2):49-56.
- 48. Halstead SB, Jacobson J. Japanese encephalitis. Adv Virus Res 2003; 61: 103-38.
- 49. Jacobson, Julie. Needs Assessment Following Hurricane Georges—Dominican Republic, 1998. CDC MMWR 1999 Feb 12; 48(5):93-97.